L. Chow

S. Gettinger, N. Rizvi, J. Chaft, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

A. Drilon, S. Gettinger, L. Crinò, 2019, The Lancet. Oncology.

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Dry Powders for Inhalation Containing Monoclonal Antibodies Made by Thin-Film Freeze-Drying

L. Chow, R. Williams, Chaeho Moon, 2021, bioRxiv.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

L. Chow, R. Hershberg, Hailing Lu, 2016, PloS one.

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

D. Camidge, L. Chow, T. Yap, 2021, The oncologist.

Concurrent cetuximab and postoperative radiation in resected high‐risk squamous cell carcinomas of the head and neck: A single‐institution experience

N. Futran, E. Mendez, G. Laramore, 2016, Head and Neck.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

J. Desai, K. Flaherty, B. Goh, 2016 .

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies

L. Chow, C. Baik, K. Eaton, 2018, Head & neck.

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

F. Hodi, Y. Bang, P. LoRusso, 2019, Journal of Clinical Oncology.

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Lajos Pusztai, Rita Nanda, L. Pusztai, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional Experience

L. Chow, A. Papanicolau‐Sengos, Shilpen A. Patel, 2016, American journal of clinical oncology.

Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.

Serafino Pantano, Michael Thomas, A. Shaw, 2016 .

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

J. Lunceford, T. Mcclanahan, R. Berger, 2016, The Lancet. Oncology.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

J. Lunceford, T. Mcclanahan, J. Juco, 2017, Clinical Cancer Research.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

S. Gettinger, F. Shepherd, D. Gerber, 2017, The Lancet. Oncology.

Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)

R. Cristescu, R. Mogg, A. Webber, 2018, Clinical Research (Excluding Clinical Trials).

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

L. Chow, C. Baik, K. Eaton, 2019, Clinical Cancer Research.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

W. Franklin, L. Chow, S. Leong, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

N. Futran, E. Mendez, L. Chow, 2018, Clinical Cancer Research.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

J. Lunceford, M. Ayers, R. Cristescu, 2022, Journal for ImmunoTherapy of Cancer.

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

V. Anagnostou, D. Collyar, L. Chow, 2017, Clinical Cancer Research.

Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers

L. Chow, S. Bhatia, R. Santana-Davila, 2017, JAMA oncology.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

L. Chow, R. Hershberg, C. Morishima, 2016, Clinical Cancer Research.

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O

Haiyi Jiang, D. Gibbons, L. Chow, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).

D. Gibbons, Dong-Wan Kim, L. Chow, 2015 .

Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study

Matthew J. Thompson, L. Chow, D. Revere, 2020, BMJ Open.

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

L. Chow, G. Pennock, 2015, The oncologist.

Small Cell Lung CancerPractice Guidelines in Oncology

C. Rudin, R. Govindan, B. Loo, 2011 .

Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

S. Gettinger, F. Shepherd, D. Gerber, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.

R. Berger, T. Seiwert, R. Mehra, 2016 .

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

Sunitinib: from rational design to clinical efficacy.

L. Chow, S. Eckhardt, S. Eckhardt, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer.

D. Camidge, L. Chow, F. Fox, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges and Successes in Developing Effective Anti-angiogenic Agents

L. Chow, S. Eckhardt, Laura Q. Chow, 2011 .

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

D. Camidge, L. Chow, S. Leong, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).

M. Ayers, R. Cristescu, R. Mogg, 2017 .

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

M. Chamberlain, L. Chow, V. Gadi, 2017, Neuro-oncology.

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

P. Hwu, J. Wigginton, A. Gupta, 2012 .

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

L. Chow, S. Eckhardt, M. Morrow, 2008, Cancer Chemotherapy and Pharmacology.

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

F. Hodi, Y. Bang, L. Chow, 2021, The Lancet. Oncology.

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.

David C. Smith, L. Chow, D. Shepard, 2014 .

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

L. Chow, O. Hamid, J. Gray, 2015 .

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma

L. Chow, C. Baik, K. Eaton, 2017, The Laryngoscope.

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

L. Chow, D. Gustafson, S. Eckhardt, 2008, Cancer Chemotherapy and Pharmacology.

Racial disparity in oncologic and quality‐of‐life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial

L. Chow, M. Guerriero, C. Baik, 2018, Cancer.

Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Lunceford, M. Ayers, R. Berger, 2016 .

Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy

N. Futran, E. Mendez, L. Chow, 2019, The Laryngoscope.

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

S. Gettinger, L. Crinò, S. Ramalingam, 2016 .

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

L. Chow, J. Infante, L. Siu, 2016 .

Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

H. Wakelee, C. Chiu, L. Chow, 2019, Annals of Oncology.

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

P. Wen, H. Wakelee, L. Chow, 2019, Annals of Oncology.

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

D. Camidge, L. Chow, D. Jonker, 2013, Investigational New Drugs.

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

M. Buyse, S. Gettinger, T. Lynch, 2013 .

Abstract 5551: SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis

D. Camidge, L. Chow, H. Burris, 2018, Clinical research.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

T. Seiwert, R. Mehra, L. Chow, 2018, British Journal of Cancer.

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

R. Doebele, D. Camidge, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer

L. Tye, D. Camidge, L. Chow, 2011, Cancer Chemotherapy and Pharmacology.

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

S. Gettinger, N. Rizvi, M. Hellmann, 2015 .

Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

J. Engelman, A. Shaw, E. Felip, 2013 .

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC

R. Heist, F. Shepherd, L. Paz-Ares, 2017 .

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Burgio, S. Gettinger, L. Crinò, 2017 .

OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).

L. Chow, V. Wu, C. Baik, 2018 .

ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of Thoracic Oncology.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.

K. Flaherty, W. Miller, Carrie Lee, 2017 .

EGFR mutations in squamous cell lung cancer in never-smokers.

C. Pritchard, L. Chow, C. Baik, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

J. Desai, Y. Bang, Tae Won Kim, 2018 .

LBA31A PHASE IB STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH HUMAN PAPIILLOMA VIRUS (HPV)-POSITIVE AND NEGATIVE HEAD AND NECK CANCER (HNC)

J. Lunceford, R. Berger, M. Dolled-Filhart, 2014 .

Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.

C. Drake, J. Wigginton, L. Chow, 2013 .

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

J. Lunceford, E. Plimack, R. Berger, 2017, The Lancet. Oncology.

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

V. Anagnostou, D. Collyar, L. Chow, 2017, Clinical Cancer Research.

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

D. Collyar, L. Chow, M. Butler, 2017, Clinical Cancer Research.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

J. Lunceford, T. Mcclanahan, J. Juco, 2017, Clinical Cancer Research.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.